Patrick C. Freitag
YOU?
Author Swipe
View article: Genome-replicating HC-AdV: A novel high-capacity adenoviral vector class featuring enhanced in situ payload expression
Genome-replicating HC-AdV: A novel high-capacity adenoviral vector class featuring enhanced in situ payload expression Open
High-capacity adenoviral (HC-AdV) vectors offer large transgene capacities and long-term expression of therapeutics but require high doses due to limited transgene expression. In contrast, replication-competent AdV (RC-AdV) vectors enhance…
View article: Activated blood-derived human primary T cells support replication of HAdV C5 and virus transmission to polarized human primary epithelial cells
Activated blood-derived human primary T cells support replication of HAdV C5 and virus transmission to polarized human primary epithelial cells Open
Human adenoviruses (HAdVs) cause self-limiting disease but are life-threatening to immunocompromised individuals. HAdV-C5 infects epithelial cells of the airways and eyes through aerosols, contaminated hands, or medical instruments, as wel…
View article: Dendritic cell targeting in lymph nodes with modular adapters boosts HAdV5 and HC-HAdV5 tumor vaccination by co-secretion of IL-2v and IL-21
Dendritic cell targeting in lymph nodes with modular adapters boosts HAdV5 and HC-HAdV5 tumor vaccination by co-secretion of IL-2v and IL-21 Open
Adenoviral vectors demonstrate encouraging clinical outcomes for B and T cell vaccines. With such approaches, multiple payloads can be delivered, beyond the antigen itself. Nevertheless, the human adenoviral vector serotype C5 (HAdV5) exhi…
View article: DARPin-fused T cell engager for adenovirus-mediated cancer therapy
DARPin-fused T cell engager for adenovirus-mediated cancer therapy Open
Bispecific T cell engagers are a promising class of therapeutic proteins for cancer therapy. Their potency and small size often come with systemic toxicity and short half-life, making intravenous administration cumbersome. These limitation…
View article: Dendritic cell targeting in lymph nodes with engineered modular adapters improves HAdV5 and HC-HAdV5 tumor vaccination by co-secretion of IL-2v and IL-21
Dendritic cell targeting in lymph nodes with engineered modular adapters improves HAdV5 and HC-HAdV5 tumor vaccination by co-secretion of IL-2v and IL-21 Open
Adenoviral vectors demonstrate encouraging clinical outcomes for B- and T-cell vaccines. With such approaches, multiple payloads can be delivered, beyond the antigen itself. Nevertheless, the human adenoviral vector serotype C5 (HAdV5) exh…
Targeting HIV-1 with CRISPR/Cas9 delivered by retargeted adenoviruses effectively suppresses viral replication Open
Integrated, intact, latent HIV-1 viruses in infected cells are the main obstacle to curing HIV-1 infections. Targeted inactivation of HIV-1 proviruses with CRISPR/Cas9 is a promising strategy to eradicate HIV-1. In addition, CRISPR/Cas9 is…
FAP-retargeted Ad5 enables <i>in vivo</i> gene delivery to stromal cells in the tumor microenvironment Open
Fibroblast activation protein (FAP) is a cell surface serine protease that is highly expressed on reactive stromal fibroblasts, such as cancer-associated fibroblasts (CAFs), and generally absent in healthy adult tissues. FAP expression in …
Zellspezifische Produktion von multiplen Therapeutika im Körper Open
Many conventional cancer therapies suffer from side effects and low efficacy, due to poor tumor localization of systemically injected therapeutics. Utilizing the adenoviral SHREAD platform, therapeutic genes were delivered specifically to …
The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody Open
Significance A challenge in cancer therapy is delivering high, consistent levels of therapeutics to tumors. Protein-based therapeutics (e.g., antibodies) are typically delivered intravenously and require multiple doses to get sufficient le…